Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season - COVID-19, RSV, Influenza
JAMA Special Communications - Three systematic reviews identify & summarise recent reporting on the effectiveness and safety of vaccines and influenza/RSV/Covid-19 epidemiology in the US.
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
"Conclusions and Relevance: COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified."
Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
"Conclusions and Relevance: This systematic review found that evidence published August 1, 2025, through June 30, 2026, continued to demonstrate that influenza vaccines were associated with reduced risk of severe disease and hospitalization, especially among older adults, infants, children, and young adults. No new safety concerns were identified."
RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season
"Conclusions and Relevance: RSV immunizations were associated with reduced risk of severe RSV and RSV-related hospitalizations; evidence among older adults suggests that RSV VE may be lower in subsequent seasons. Reported adverse events of special interest (including GBS and preterm birth) were consistent with prior reviews. The results of this updated review are both consistent with previously reported evidence and provide new insight into several aspects of RSV immunizations."
Share
Topics
Mediums
